

# Biomarkers of Tuberculosis – A Review

Ritika sharma

*University Institute of Pharmaceutical sciences, Mohali, Punjab*

*E-mail: [sharma.ritika88@gmail.com](mailto:sharma.ritika88@gmail.com)*

***Abstract: According to recent World Health Organization reports, Tuberculosis is regarded to be the most severe disease caused by infection. There are significant drawbacks to the testing used for TB diagnosis and there is no accurate point-of-care (POC) diagnostic examination. New methods are required worldwide to controlling tuberculosis (TB). In general, new diagnostic methods and new biomarkers are necessary to assess both pathogenic and host main elements of an infection response. Biomarker-based or multiple marker biosignature-based tests, preferably conducted on blood or urine, for the identification of active TB may help achieve the target drug profiles recommended for point-of-care testing by the World Health Organization. Here I review The identified forms of biomarkers included antibodies, cytokines, metabolic markers, mycobacterial antigens and volatile organic compounds and the different biomarkers of tuberculosis, like, LAM, IFN-g, mycolic acid, antigen 85, different VOCs, Rv1681 protein, CFP-10, granzyme A***


***Keywords: antigen 85, neopterin, granzyme A, mycolic acid, LAM***

## 1. INTRODUCTION

Tuberculosis is a killer infectious disease. Tuberculosis in humans and animals can result from bacterial infections<sup>[1]</sup>. Tuberculosis is the major killer due to communicable diseases, exceeding HIV and AIDS, it literally spreads air through infected people, although this is curative and preventive. The probability of spreading infection from TB patients to healthy individuals depending on risk factors such as HIV, the economic standing, unemployment, alcohol consumption, smoking and the amount of vitamin D3 in the serum. Understanding the effective risk factors for tuberculosis is a key step in reducing this virus while developing a mechanism to assess the impact of risk factors and the intensity of their association with tuberculosis is very critical. Tuberculosis primarily attacks lungs (pulmonary tuberculosis), but it can damage various organs. Tuberculosis diagnosis is also limited due to several medicinal sources, too. One disorder in the sequence is tuberculosis caused by mycobacterium tuberculosis. TB bacteria can exist inside the body without causing a person to become sick. This is called infection with latent TB. People who are infected with the latent tuberculosis infection does not feel sick, having no signs of Tuberculosis and are unable to transmit TB bacteria to others. Many people suffering with latent Tuberculosis infection appear as developing TB disease. Persons with TB may transmit the bacteria to others, feel ill, and can develop symptoms of nausea, night sweats, cough, and weight loss. Persons with TB may transmit the bacteria to others, feel ill, and can develop symptoms of nausea, night sweats, cough, and weight loss. WHO's tb statistics show estimated 10.0 million reported cases of TB disease (also known active TB) in 2018<sup>[3]</sup>. As per the 2018 WHO report Ninety % was adults (age > 15) 57 percent were males 32 percent were females and 11 percent were children. 8.6 percent were HIV-positive people. Eight countries make up

two-thirds of India (27%), China (9%), Indonesia (8%), the Philippines (8%), Pakistan (6%), Bangladesh (4%), Nigeria(4%), south Africa(3%)<sup>14</sup>

### country wise data of 2018




Preventive diagnosis for developing active tuberculosis (TB) in high-risk populations is necessary for TB prevention and removal; furthermore, there are no effective methods suitable for determining the efficacy of preventive treatments.

Pulmonary tuberculosis diagnosis usually takes at least 6 months, contains key medications of varying different doses, and is thus marked by compliance and adherence issues. There is still a lot of enthusiasm into the shortening the length of treatment either by using current drug formulations or by adding new medications, as well as a renewed interest in both reusing old medications for TB treatment and use host-directed treatment as an alternative way. Biomarkers are the objective attributes that signify a natural biological process or pathogenic process. A reasonable biomarker for identification or multiple indicator bio signature for TB will be a needed pathogen or host marker appropriate to the basic process of the disease. Active Tuberculosis diagnosis is dependent on detecting Mtb from sputum, and relies on the existence of necrotic infection foci near to the airways. The diagnosis is then based on sputum smear and history, and more recently positive MTB / RIF tests by Gene Xpert. Microscopy is common and extremely specific, yet lacks understanding, with a lack of detection in more than one third of the treatment required. Mtb culture seems to be the gold standard for Tuberculosis care, also it can only yield results after a limited period of time (3-4 weeks). All diagnostic tests on tuberculosis require Mtb-positive sputum, while many active TB patients need Mtb-positive sputum. Along with HIV-co-infected people, patients with diabetes and children Mtb-Positive sputum are not present. For those diagnosed with sputum, there are various non-sputum based-tests for active TB diagnosis, relying on serum, plasma, urine or stimulated or unstimulated blood. Mycobacterial lipoarabinomannan (LAM) as both an active TB as well as latent Tuberculosis LAM diagnosis indicator, the large lipoglycan (a multiglycosylated expansion in phosphatidylinositol mannoside (PIM) glycolipids) of the mycobacterial cell membrane was shown to be found in urine of persons contaminated with M.Tb<sup>15</sup> We can distinguish biomarkers related to the pathogen and to the host. On the pathogenic point of view, Mycobacterium tuberculosis compounds can be found

specifically in blood, sputum or urine of pulmonary Tuberculosis infected individual with a greater accuracy than Mtb can often be identified in the urine samples and blood sample. Modern tuberculosis treatment is being established, created and implemented but the Tuberculosis program by WHO has been driven by concerns about the selling of the inadequate in vitro diagnostic test. Xpert MTB / RIF for treatment of children and adults infected with pulmonary tuberculosis and extra pulmonary Tuberculosis. There are two kind of test to detect TB bacteria in the body: TB skin test and TB blood test The positive(+) skin test and positive(+) blood test for Tuberculosis just indicates that a individual had Tuberculosis infection .the symptoms of TB include a low grade fever, night sweats, weakness or tiredness and weightloss, if TB in lungs, the person may also cough, have chest pain, shortness of breath or might be coughing of blood. Other symptoms depends upon the part of the body affected by TB germs Tb caused by bacteria is micobacterial tuberculosis and cause lungs disease called Pulmonary tuberculosis tuberculosis is mainly of the brain, spinal chord, lungs, reproductive Organs, joints and bones, heart.

Some diagnostic tests <sup>[6]</sup> are x ray, MRI, Blood test, Tb skin test . Monitoring of the treatment for tuberculosis is important in therapeutic decision-making and it appears That the host biomarkers perform a major function. Tuberculosis-diagnosed patients usually undergo a four-month course of treatment , regarded as the acute period, preceded through a four-month isoniazide and rifampicin maintenance process. Nevertheless, some patients may suffer recurrence of infection following 6-month-long anti-TB treatment .But still has elevated chance to multidrug resistant tuberculosis or drug resistant Tuberculosis. This 6-month period can result in prohibitive clinical management delays. There are aproximately 558,000 case with rifampicin opposing Tuberculosis were identified by the WHO in 2017, 82% of which are MDR-TB infected. This has caused major problems for patients because they continue Over a much more period of time (i.e 18month to 24 months) to have been diagnosed via 2nd line medicines ,despite the fact that their rate of survival was only <50%.Biomarkers that suggest successful therapy in the early therapeutic process and at the end of therapy that forecast recurrence will significantly enhance clinical prognosis. Development of a successful novel vaccine and novel drugs with shorter treatment time as well as easy and more precise diagnostic tests are of vital importance for maintaining global control of TB diseaseThe reduced cost, minimally interfering, greater responsive, anti sputum focused, and As well as accurate Treatment for Tuberculosis procedure using readily available biological specimens including blood and urine is therefore desperately required. In general, Biomarker may be categorized onto: (1) Mycobacterium tuberculosis elements, (2) antibodies respond to Mycobacterium tuberculosis antigenic determinant, (3) cell immune responsd for Mycobacterium tuberculosis antigenic determinant, and (iv) objective "omics" proceed towards<sup>[7]</sup>. Mtb exposure to suboptimal concentrations of the medication threatens vigorous replication and proliferation of bacteria, increased transmission rates, and drug resistance growth.


Initial symptoms of lungs are 1) chronic cough (2)weight loss (3)fever (4)night sweat (5) Chest pain (6) fatigue. Initial biomarkers of bones tb are (1) localized (2) low grade fever (3) felling of unwell (4) Weight loss Initial biomarkers of spinal chord (1) pain (2) stiffness (3) fewer Spine tuberculosis may cause paralysis and spine deformity, the spine deformity is faster In children because of children bones are softer than adults.The symptoms of tuberculosis are shown below



Review of literature:

**BIOMAKERS :**

A biomarker is a feature that can be calculated as a predictor of natural biological processes or changes (Walliset al.2010). Such biomarker of tuberculosis is typically components of both host as well as pathogenic origin primarily for infectious diseases. Much of the biomarkers found through MALDI TOF-Mass Spectriscopy are molecular protein of 15 kDa or less for intact bacteria. These proteins are typically intracellular, abundant, and essential. Findings reported by Wanget al.(2004) and Welhametal.(1998) indicate that some proteins (including ribosomalproteins) can be chosen for bacterial recognition as unique retained biomarkers.Aclinically relevant biomarkers must follow three critical criteria: include reliable, consistent tests at acceptable cost and with a fast processing time; provide evidence that is not accessible from clinical evaluation; assist in medical decision-making;The following features will be the proxy marker: have a strong relation to disease pathogenesis; forecast a long-term result in the absence of effective therapy; show improvements in the early stages of treatment with predictive value; catch the full impact of medication on the



disease process; be independent of the method of treatment system .

#### *Breath biomarker.*

Tuberculosis disease can thought as outcome from the liberation of volatile organic compounds(VOC) metabolites which can be found within individual breath . Breath such as urine have the sputum additional benefit for convenience ,non-invasive sample assemblage ,prospectivel utility within population by which this Might be harder to acquire standard sputum sample. device such as DiagNose, using a set of metaloxide detectors of volatile breathable contaminants. Breath VOCs provided obvious biomarker for the active pulmonary tuberculosis(tb) which include the Oxidative stress compounds (that are alkanes and the alkane derivative products) together with excitableness M metabolites. Tuberculosis (cyclohexane derivative product as well as benzene derivative product)<sup>[8]</sup>.Methyl p-and methyl nicotinate. It is a by-product of the metabolism of Mycobacterium tuberculosis and should therefore Be associated with anyone who has active Tuberculosis regardless of age. Such VOCs do not appear to be released by other respiratory tract bacteria; do not appear to be present in the natural atmosphere at large concentrations. They were found at high concentrations in breathf patients with TB but not in appropriate measures. Moreover, the lack of resources at the point of care to accurately quantify different VOCs was a major obstacle to further testing and use of these VOCs as a biomarker for TB diagnosis<sup>[9]</sup>. In breath, volatile organic compounds (VOCs) that include marker for the active pulmonary Tuberculosis specifically extracted through the contagious tissue (e.g., Mtb metabolised) Or even Contaminated host (e.g. oxidative stress products). The breath check basing upon identification as well as quantification for VOCs recognized possible biomarker for the active pulmonary Tuberculosis in indicative high-risk subjects with 85 percent accuracy<sup>[10]</sup>

#### *Urine biomarker*

Urine is a non-invasive therapeutic samle that is especially beneficial for patients with challenging sputum (e.g. children) or poor yield (e.g. indivisual suffering from HIV). The urine were found to possess many pathogenic substances biomarker . transenal mycobacterial DNA were tiny DNA parts of the bacterial genome produced through cell lysis which were identified within the urine of the infected person. A recent research shows

that variations in tryptophan, phenylalanine, and tyrosine is major differences in urine in active pulmonary tuberculosis<sup>[11]</sup> However, this research was constrained by a small sample of TB participants, and did not involve a sample of validity<sup>[12]</sup>. The possible differential urinary biomarkers for active Tuberculosis, that are N-acetylhexosamine, neopterin, diacetylspermine, including sialic acids. They observed certain possible biomarkers differed toward appropriate monitors against active pulmonary tuberculosis. After correction for age, class, and symptomatology, those biomarkers remain substantially different. However, neopterin, kynurenine, as well as sialic acids throughout the blood, urine, & pleural fluids among Tuberculosis patients were observed to have been elevated individually. Neopterin has also been identified as a possible risk factor towards HIV disease. Neopterin has been shown to be a reliable marker of cell-mediated immune reactions; thus, neopterin levels in different body fluids have a diagnostic relevance in several diseases, including T-lymphocyte and macrophage diseases<sup>[13]</sup>.

Biochemical Characterisation of protein Rv1681 as well as medical confirmation to protein Rv1681 is diagnosis risk factor to active pulmonary tuberculosis. Peptides resembling the amino acid sequence for the Rv1681 protein is identified from urine sample of affected patient. THAT M. The Rv1681 tuberculosis protein and the other three proteins were the M. Tuberculosis protein risk factors were recorded to date which have been detected direct through urine sample of Tuberculosis patients in areas in which Tuberculosis is prevalent Such a test would be able to differentiate amongst active as well as latent patients. This will also include an important new global disease control policy. In specific, an antigen identification test using urine may potentially enable the diagnosis of POC TB—for the adults patients with pulmonary TB, even in communities that are hard to treat, like in kids and the adult patients with extrapulmonary Tuberculosis ,LAM, is the major lipoglycan of the mycobacterial cell membrane Was found to have been contained in urine of the Individuals suffered withTb .LAM form an integral component of M.TB Cell wall / envelope with up to fifteen per cent of the bacterial volume. It is consisting of the a mannan center. Additionally , with M.Tb. The most of terminal arabinose units of the Arabin chain are connected to them a shorter two –four mannose carrying oligosaccharides termed "mannose capping motifs;" that type of LAM is classified as ManLAM . LAM has major, different immunomodulatory properties <sup>[14]</sup>The virulence element aligned with M pathogenesis is known to be. Infection with tuberculosis; LAM is found in body fluids during mycobacterial infections that provide a possible biomarker for the identification of infected people. Furthermore, the immune reaction to LAM may act as a diagnosis method . Tests showing M. Tb antigens in laboratory sample may theoretically deliver many advantages with regard to a specific TB biomarker <sup>[15]</sup> .Urinary LAM research has produced a great deal of interest and a great many publications. The higher, and thus measurable, urine concentration of LAM in people with advanced immunodeficiency was believed to be focused on a higher mycobacterial burdenand systemically M.Tuberculosis dispersion. It may logical that in patients along with a more authenticated TB, fewer LAM would be excreted. Another explanation may be that early HIV infection with associated mycobacteriuria affects the renal tract. More research is necessary to come to a consensus over this issue. Urinary LAM was also stated to have been connected by inflammatory syndrome with immune reconstitution(IRIS) <sup>[16]</sup>. preceding to activation to antiretroviral treatment , this was suggested that urinary LAM identification might indicate its progression for TB IRIS. IThe synthesis of LAM in urine as well as IRIS reinforces the belief that a high concentration of urinary LAM is a dispersed disorder with a strong pathogenic charge. Taking into account that LAM in the urine could leastways partially indicate that bacterial load well into the bodies, a calculation of the accumulation of LAM was recommended as a method for measuring the efficacy of anti-TB therapy.

Although the urinary content of LAM from HIV negative(-ve) young adult TB infected persons are minimal, And analytical specificity for system employed is utterly critical in most situations. We, among others, find that the real LAM concentration in urine is between fifteen pg.mL and fewer hundred ng.mL. Low pH occurs more commonly in malnutrition, also it can decrease LAM detection capability. The positive impact on the LAM We found few positive(+ve) impact to the indicator of LAM by changing the pH to a neutral level. Some, postulated the stronger the LAM signal would be the more found that urine at morning concentrated the urine would be. Indeed, a recent study time processing (which is higher strenuous) increases the safety of urinary lateral flow LAM assay in hospitalized TB and HIV-coinfection patients. Thus, it appears that the matrix does not block the LAM signal in people suffering from both HIV/AIDS, co-infected and possibly greater amount of LAM present in urine, but in the patients which is not infected with HIV (possibly have lesser amount of LAM) the matrix influence is controlled by concentration. Hypothesis that the matrix effect to signal of LAM can be minimized by diluting urine, a typical approach for reducing matrix consequences in biological assays<sup>[17]</sup>. In addition, the LAM signals in diluted urine acuminate when LAM is enhanced. Nevertheless, Sample dilution with quite small quantity for excreted LAM is unsuccessful because LAM would be depleted within detectable standards<sup>[18]</sup>.

#### *Sputum biomarker*

Numerous Mycobacterium tuberculosis proteins were suggested as possible markers for sputum, but none in the real specific test have yet established Tuberculosis antigens like those of CFP-10, ESAT 6, MPT-64 were developed with aptamers which attach with key target peptides and can be identified by immunoassay-related enzymes. Similarly tb-specific protein such as antigen 85 was introduced as a diagnostic marker. Other sputum markers include host-generated enzymes and markers to rely the infection. Some eg, interferon-g displaying a dual utility to tuberculosis diagnosis in respiratory sample. While it is not helpful in the blood, interferon g has been seen to be more effective in the diagnosis in tuberculosis through the extrapulmonary sample including the fluid in chest and body fluid. Additionally, the sputum and extrapulmonary samples tested adenosine deaminase and alkaline phosphate levels, and may not be classified as a separate indicator for tuberculosis. The testing integrating numerous biomarkers into some kind of sample test series that come in beneficial as something of an initial test check for tuberculosis<sup>[19]</sup>. Active TB diagnosis is concentrated upon identifying Mtb in sputum, which relies on the existence of necrotic infection foci near to the airways. Subsequently, the diagnosis is centered on sputum smear and culture, and more recently positive GeneXpert MTB / RIF tests. Microscopy is partly available and extremely accurate, but lacks specificity.<sup>[20]</sup> A more commonly adopted diagnosis procedure till present is acid fast bacilli (AFB) sputum microscopic identification, with low sensitivity varying from 34% to 80%. This is due to the AFB test probably needs 10,000 bacilli/ml of sputum for yield a successful outcome. Unless the bacilli amount dropped beneath trimmed-off, there is only < 10 percent risk of achieving an AFB positive test. Sputum culture appears comparatively higher resilient than that for AFB sputum test but it does have a processing time of several weeks. In addition, Mtb culture includes facilities of Safety from exposure to infectious agents stage 3 that is increasingly accessible throughout endemic Tuberculosis regions. The fundamental advancement throughout the diagnosis of Tuberculosis is the newly designed PCR-based approach for amplifying the Mycobacterium tuberculosis gene called GeneXpert MTB / RIF. This testing isn't only possible, it needs fewer preparation to lab technicians, although it is strong enough to kill "two birds with one stone" through jointly identifying Mtb as well as rifampicin sensitivity under Two hrs. The use of these, moreover,

is usually limited just for active pulmonary Tuberculosis, but not to latent tuberculosis infection. Furthermore, all the diagnosis approaches focused on sputum had their own inherent shortcomings in which these are scarcely effective for diagnosis to extra-pulmonary Tuberculosis disease. Consequently, for analysis of extra-pulmonary Tuberculosis disease relies upon examination for the specifically tissues and certain several biological materials, including Fluid in the chest and bodily fluid that also requires interfering course of action. This may be a major concern as the prevalence for extra-pulmonary Tuberculosis in few developed countries varies from 1 to as more as 3 including sampling also implies interfering course of action. Hence, its use as the host markers representing the pathological pathway / host immune responses for active Tuberculosis, extra-pulmonary tuberculosis and latent tuberculosis may have been a safer choice<sup>[21]</sup>.

**Mycolic acids** Lipids make up about 60 per cent of the dry mass of the cell wall of mycobacteria. These act as a barrier to permeability which constitutes the very first line of defense against the immune system of the host. Mycolic acids, long chains of arabinogalactan-esterified fatty acids, are among the essential lipid Components of the mycobacterial cell wall. Mycolic acids is appealing as diagnostic indicators against tuberculosis infection as they would be extracted from pathogens, give specifics on bacterial pathogens, inhibit associations between host and pathogen yet this is not chemically reactive.<sup>[22]</sup> Mycobacterial cell walls contain various mycolic acid types that are used for bacterial taxonomy and identification. The most widely distributed form of mycolic acids in *M. tuberculosis* is alpha-mycolates, which contain no oxygen substitutions in their chains. Keto- and methoxy-mycolates, characterized by cis and trans cyclopropane rings in the proximal positions, are significantly less common. Many studies have confirmed the presence of mycobacterial mycolic acids in both modern and ancient TB, suggesting the use of mycolates as sensitive biomarkers of the disease<sup>[22]</sup>. Mycolic acids seem to be appropriate diagnostic indicators of mycobacterial infections for many reasons. First, the compounds are present in the bacterial cell wall at a high concentration, regardless of the conditions of growth. Secondly, these are unique to bacteria, but are not developed in the human body. Second, the chemical stability and fairly simple extraction of mycolic acids allows for the use of chemical analysis methods for their studies. Part of this is due to their hydrophobic behavior and diverse chemical structure. A surface plasmon resonance (SPR) biosensor inhibition test abbreviated MARTI (mycolic acid antibody inhibition in real time) has allowed the detection of serum antibodies in mycolic acids. While it has been observed that mycolic acids are secreted during mycobacterial infection, which induces the development of particular antibodies, no validated immunoassays have been produced to detect these anticorps<sup>[23]</sup>.

**CFP -10** *M. Tuberculosis* has a complex, lipid-high cell membrane containing 5 established form VII excretion method that have designed to transfer substances effectively through bacterial cytoplasm from additional cellular extent. Also better observed for secretion regimes are the 6-kDa initial excreted antigenic aim (ESAT-6) excretion process 1 (ESX-1), that are put into code in the mycobacterial genome by region of distinction 1 (RD1) and is necessary to *M. Virulence tb*. And ESX-1 also liable to transition of the heterodimeric protein compound contain ESAT-6 (generally known as EsxA) and a 10-kDa grain filtrate protein (CFP-10, also known as EsxB or *M. tuberculosis* particular antigen 10 [MTSA-10]) to natural atmosphere. CFP-10 is an antigen secreted by *Mycobacterium tuberculosis* in 10 kDa. With ESAT-6 it forms a heterodimeric complex 1:1. Both genes are expressed from the bacterial genome region RD1 and emulate a key role throughout the disease virulence. The CFP-10 contains a C-terminal sequence allowing for the complex to be secreted through bacterial cytoplasm. Also the compound is assumed to breakdown through acidic situations, e.g. within the phagolysosome a complex ESAT-6/CFP-10 is an



integral Rate of transmissibility in Mycobacterial Tuberculosis, with Mycobacterium Marinum. This tends to provide a membrane- recuperation function, which leads to bacterial evacuation through the phagosome to that of the macrophage cytoplasm and causes infected cells necrosis as well as bacterial spreading into neighboring sites <sup>[24]</sup>. Chemotaxis of neutrophils and activation of NADPH-oxidase caused by CFP-10. Neutrophils are permitted for transfer around the membrane to being well comprising the -ve regulation buffer, fMLF (10<sup>-8</sup> M) as the +ve regulation, either CFP-10 in the amounts described as PtX Ca<sup>2+</sup> + signal sensitivity induced by CFP-10. Neutrophils have been filled by Fluo-3 also FuraRed as well as controlled by PtX that suppress & leave unchecked G-proteins. Latent Tuberculosis-related antibodies were major causative agents for cell-intermediate immune system response in latent Tuberculosis pathogens, while in active tb and latent TB instances, ESAT-6/CFP-10 would be a potent inducer for cell-intermediate immune reaction. From several parameters, Across both active as well as latent instances, IgG antibody towards ESAT-6/CFP-10, Rv2031 & inactivity-affiliation antibodies were observed. Among sera of specimens containing culture-approved pulmonary tuberculosis, imply optical density (OD) concentrations to IgA vs ESAT-6/CFP-10 and Rv2031 was substantially greater comparable to stable Mtb-infected or anti-infected human beings (P < 0.001). This imply Optical density concentrations for IgG versus ESAT-6/CFP-10 as well as Rv2031 among sera of specimen with culture-approved PTB were also considerably higher relative to secure Mtb-infected specimen as well as non-infected specimen (P < 0.05). In sera of stable Mtb-infected patients. The average OD levels in IgA towards antibodies have been better contrast to those of uncontaminated human beings. Optimistic associations (P less than 0.05) were observed amongst the amount of IFN- $\gamma$  produced within QFTGIT assay & serum IgA OD levels towards the antibodies in stable Mtb contaminated concern. Which demonstrates that ability for the IgA reaction to antigens ESAT-6/CFP-10 including Rv2031 to distinguish against stable cases of potentially infected and uninfected Mtb against therapeutic TB. The response of the IgG & IgA antigens to ESAT-6/CFP-10 also Rv2031 was substantially greater among specimen for culture-authenticate PTB contrasted with protected Mtb-contagious disease and un contagious disease instances. For subjects contaminated with Mtb and those not affected, the IgA antibodies reaction towards both antigens differs <sup>[25]</sup>.

### *Blood biomarker*

Blood is fairly easy to collect and, unlike sputum, is a medium available during recovery for biomarker interventions. Inflammation and disease markers dependent on the blood are also quantitative, offering an ability to boost predictive capacity by incorporating several biomarkers into predictive biosignatures. Transcriptomics has regional coverage of host reactions, and is widely used in work on biomarkers of TB. One downside of microarray technology are the deficiency for an complete as well as thorough measurement to gene expression. Current intense -succession techniques have comparisons based on quantity as well as comparisons based on qualities evidence for gene or genomic Structure down to a particular single level of nucleotide. RNA sequencing would be increasingly to gain ground also has greater sensitivity to more precise parameters for transcription rates but also their isoforms than microarrays because it sustains sample-dependence. RNA-seq has been used to research the changes of the host leading for mycobacterial contamination and will have presented valuable perspectives. E.g. concurrent host and pathogen RNA sequence in Mtb affected Thp1 cell suggesting simultaneous activation of Mycobacterium bovis BCG (Bacillus Calmette) cholesterol deterioration genes and compensate increasing the response to a stimulus of host from the beginning of cholesterol producing of a chemical compound from living organism. Recently a full blood signature has been identified that may forecast the

likelihood of initiate the active tb of individuals suffered from latent disease has spotted by RNA. While the immunological response to Mtb should be predominantly centered on the lung, its pathological status is reflected by circulating immune cells in the peripheral blood. Entire blood transcriptomic statuses offer regional perspectives onto the host immune response to tuberculosis these act like important resources for deduce the fundamental molecular plays of infection.<sup>[26]</sup> Interferon g release assay including Quigan Quantiferon tuberculosis gold through tube assay as well as oxford immunotec TB spot .Tuberculosis testing evaluate the in vitro secretion for interferon g into blood cells through affector T Lymphocytes when they are stimulated to MTB specifically by antigen. While IGRA was designed to substitute the skin test for detection of the diagnosis for latent tuberculosis infection (LTI) .this will be of minimal utility in active tuberculosis diagnosis because they cannot accurately differentiate among latent disease versus active disease and can have low sensitivity particularly in infants and sufferer with immunocompromise. Combined successful tb susceptibility analyzes range from 35% to 92%. Certain biomarkers which are blood basing for the tuberculosis disease , as well as intercellular adhesive neopterin dissolved elements and a substance produced by many types of cells in the body (procalcitonin), were suggested for analysis tool as well. The biomarker check based on blood that did not prove useful is serology<sup>[27]</sup>

The MoeX protein, unique to M. Clinically confirmed tuberculosis complex as an aggressive pulmonary TB diagnosis biomarker The more acceptable biomarker to detection for active Tuberculosis disease applying the traditional enzyme-linked immunosorbent assay are Ag85 andESAT6 along with LAM. Dhanasekaran et al. reported high evi-dence in children aged <3 years to use RAB33A protein for possible marker for distinguishing latent tuberculosis from active Tuberculosis . Any promise for distinguishing kids suffering from latent Tuberculosis from uninfected kids utilizing CD4, TGF-b1,IL-2and IL-13 cytokines as The body's integrated response to an antigen as a biomarkers has also been demonstrated. The specific tran-scriptional profiles that can differentiate individual infected with latent disease stable contributors and active TB infected individual. genetic code linked with adaptive immune system response, programmed cell death & function of NK cells, like those of FccRIB, have been expressed differently in these various stages among the genes<sup>[28]</sup> . **IFNg** secretion by antigen-specific CD4 T cells has been used as a protective biomarker although available data reveals that while IFNg seems to be an important part of the immune system response, it's not a effective protective biomarkerIn comparison, increased output of IFNg in increased CD4 + T cells indicated the bacterial load, instead of the defensive strength.A recent analysis in humans indicated that IFNg does not associate with BCG-induced child safety, although it is a reliable immunogenicity marker<sup>[29]</sup>. The interferon (IFN) $\gamma$  inducible protein 10 (IP10) was found to have been risen in the unstimulated plasma present in kids and young adults suffering from active Tuberculosis . IP-10 developed mainly in monocytes/macrophages but also plays a key role well into the transportation for Th1 t cells with enflamed foci by contact with such a CXC chemokine receptor. Ten Elevated position for IP 10 have been identified within TB patients with pleural outflow also lungs tb granulomain . Regardless of IP-10 will differentiate among both active Tuberculosis and LTBI has been disputed. IP-10 plasma stages had been greater inactive TB than that in latent tb infection, but also show decreased on the ending of M.tuberculosis diagnosis.Moreover, discordant reports have been observed on certainly. IP-10 make difference between active Tuberculosis and latent tuberculosis infection. For active TB, IP-10 plasma levels were higher than in LTBI, which indicated the decrease on the ending of M. Tuberculosis diagnosis<sup>[30]</sup> . Niveaus of active TB were slightly higher in rheumatoid arthritis patients than in LTBI<sup>[31]</sup>. Alternatively, TB particular antigen induced IP-10 cannot differentiate amongst


active Tuberculosis as well as latent tuberculosis infection in kids infected with the IGRA (Interferon Gamma Release Assay) [32][33]. Mycobacterium tuberculosis identification by mass spectrometry. The new clinical TB laboratory has developed MS approaches that allow for rapid detection and real-time tracking of the onset of an epidemic. The use of MALDI-TOF-Molecular spectroscopy for effective diagnosis to mycobacterial TB. Time emergency surveillance has been discussed in a few previous studies. Several recent research have investigated the use of MALDI-TOF-MS to reliably classify mycobacteria. Hetticket in 2004 used MALDI-TOF Molecular spectroscopy in observation of 6 mycobacterial category, showing an unequivocal recognition of each category on the basis of its unique m/z values and protein profile. 16 mycobacterial strains were unambiguously described by the m/z values based upon MALDI-TOF-Molecular spectroscopy, characterizing bacterial strains in either M. Non-tuberculosis tuberculosis with 100% precision. A analysis carried out by Pignoneet in 2006 indicated the MALDI-TOF-Molecular spectroscopy is the fast as well as efficient process. Once thirty seven strains of quick grow also slow grow mycobacteria were studied, type particular specimen were observed in thirtysix isolates. That analysis supported efficient, precise strain-level differentiation. Many of the ions found in this study have the molecular mass span from 500 to 2000 Da that are thought to have been little polypeptides & lipids, cell wall components that may serve as biomarkers.

The complex of **antigen 85** (Ag 85) constitutes a significant mycobacterial secreted antigen although it has also been detected in the mycobacteria cell wall. This complex consists with three separate proteins-A, B, C coded with 3 distinct genes (that are fbpA, fbpB, fbpC2). The proteins A, B and C are usually distributed in a ratio of 2:3:1 however, the ratio might depend on the environmental conditions [34] among all types of mycobacteria, regardless of their pathogenicity; These three Ag 85 proteins have the binding capacity of human fibronectin, an extracellular glycoprotein matrix that decreases phagocytosis of Mycobacterium tuberculosis the macrophages also promotes the adherence as well as dissemination for pathogen in tissue. The Ag 85 complex were observed in different biological samples, in particular blood, urine, sputum, and cerebrospinal fluid from that Patients affected by tuberculosis. Although several mycobacterial organisms express the proteins, their possible applicability as new biomarkers of TB and as candidates for vaccines requires comprehensive research. The Ag 85 complex serum identification yielded 96 per cent and 14 per cent sensitivity among TB and non-TB patients, respectively. In tuberculous meningitis, elevated levels of the Ag 85 were also found, indicating the possibility to use this protein becoming diagnostic screening tool for this tuberculosis form 1 Sputum surveillance Ag 85 can be a significant supplement to antituberculous therapy surveillance after Ag 85 complex was detected in patient's sputum in few days after treatment initiation. However, the rapid removal of the Ag 85B RNA from sputum in cured TB patients did not cause the antigen to be regarded as a predictor of relapse [35]. Ag85B in patients with active TB found to be considerably greater than that of LTBI (latent tuberculosis infection) [36].

Cytotoxic substances including granulysin, perforin as well as granzymes formed from cytolytic Lymphocytes contribute significantly for the immune response of tuberculosis (TB). We examined Granzyme A phases within plasma collected through QuantiFERON-TB Gold Through tube testing of individuals with the active Tuberculosis infection but also respondents from latent Tuberculosis infection (LTBI) searching for novel biomarkers of TB. **Granzyme A** plasma rates among Tuberculosis victims was significantly smaller than that of the measurements observed among LTBI respondents once the unstimulated levels subtracted the antigen-responses. Potential granzyme A plasma volume derived as an antibody / pathogen biomarker from activated entire bloodstream matching people against LTBI

subjects with active Tuberculosis virus. The curve review of the recipient user properties compared Tuberculosis cases with LTBI classes revealed which the assay's susceptibility as well as specificity have been 29.41 percent and 94.74 percent at such a ripped-off valuation of granzyme A less than 3.425 pg / ml, accordingly. moreover, Pitabut et al. have tested ELISA concentrations for granulysin, perforin, granzyme-B including IFN-like in individuals including lungs Tuberculosis either with or without HIV co-infected . In TB patients, concentrations of granulysin as well as perforin circulated are smaller than that of healthy subjects, while concentrations of granulysin as well as perforin were greater in TB HIV co-infected patients as compared to other population, this indicates activation of the immune response among TB-correlate HIV pathogens<sup>[37]</sup>. Which the serum granzyme A values were considerably lesser among people who suffering from active Tuberculosis infection rather those in LTBI cases. Taking advantage for the immense particularity for the granzyme A test, this molecule is specifically identified as a TB infection / illness marker<sup>[38]</sup>

TB TESTs



There are many types of testing that are used to assess whether a person has been diagnosed with TB bacteria: the skin test for tuberculin and the blood test for TB. A health care provider of an individual should select which TB check to use. Factors in deciding which test to use include the purpose for testing, the number of tests and the cost. In general, testing a person with both a skin test for TB and a blood test for TB is not prescribed.

Tuberculosis skin test: The skin test for Mantoux tuberculin is a procedure for determining if a person has been diagnosed with TB bacteria. The TB skin check is conducted by inserting a

small volume of fluid (called tuberculin) on The bottom section of the forearm into the blood .A individual who undergoes for tuberculin skin check will return within 48 to 72 hours to receive a response on the arm from a professional health care provider.The effect would depend on the size of the raised, rough field, or swelling. Positive skin test: This indicates that the individual's body can be contaminated from TB pathogens . Further tests are required to decide if a person infected with latent TB or TB disease.Negative skin test: This indicates the person's body has not responded to the examination, so it is unlikely the latent Tuberculosis inflammation & Tuberculosis Contagion may occur<sup>[39]</sup>.

Tuberculosis blood test:Interferon-gamma release assays, or IGRA, were also considered tests through blood for TB. Two blood checks for TB have U.S. certification of FADA and available in US: A QuantiFERON –TB Gold In-Tube (QFT-GIT) as well as T-SPOT examine .TB (T-Spot) test. A health care worker must collect a patient's blood for examination and tests, and give it to a laboratory. Positive blood test for TB: Which indicates the person was diagnosed through TB microbes . Specific test were required for decide if a people suffering from latent Tuberculosis & TB contamination .Negative blood test for TB: that showing individual's blood cannot respond for the particular test , so LTB as well as TB infection can impossible. It is often suspected that IGRA test is not effective in individuals with HIV<sup>[40]</sup>

Sputum smear:Smear sputum microscopy is always the first method that can be seen with nations where the more TB contamination risk. Sputum the thick fluid formed in the lungs and in the airways which leads to the lungs. The person who coughes normally gathers a collection of sputum. In 2012, it was proposed that two specimens could be obtained on the same day without any lack of accuracy <sup>[41][42]</sup> To perform the test, a very thin coating of the sample will be added For the experiment, as well as the slide besmirch were analyzed for signs of the TB bacteria under a microscope. Sputum smear microscopy is inexpensive and easy, and people can be taught to do so fairly rapidly and easily. Additionally the findings will be published in hours. However, the exposure is only around 50-60%<sup>[43]</sup> The diagnosis rate could be much poorer among nation among the more incidence for lungs TB as well as HIV contagion because most HIV or Tuberculosis co-infected cases often quite lesser rates for TB contamination in their sputum and therefore are reported as sputum negative. Chest X ray: When a person has had TB bacteria that have induced inflammation in the lungs, an irregular aura can be evident on an x-ray of the chest.<sup>[44]</sup> Sometimes, an X-ray may clearly reveal acute pulmonary TB. What it does reveal, however, is not clear. A standard X-ray in the chest can't rule out additional pulmonary TB.Also, there might be a lack of X-ray facilities in countries where resources are more limited. Fluorescent microscopy: Use fluorescent microscopy is one way to make sputum measurements more accurate. The smear are lit via a quartz halogen / wide-pressure mercury vapor lamp with a fluorescent microscope, enabling viewing of an more wider area for the smear, leading in easier examination of specimens. One downside is that a mercury vapor lamp is costly and lasts only a very short amount of time<sup>[45]</sup>.

#### TB DIAGNOSE

TB disease can be treated by taking several drugs for 6 to 9 months. There are currently 10 drugs accepted from U.S Administration of FADA for treating TB, of the approved medicines , are 1<sup>st</sup> line anti tuberculosis agents which form the core of treatment regimen are:

- Isoniazid
- Rifampin
- Ethambutol

- **Pyrazinamide**

Isoniazid is a prodrug, that prevents mycobacterial cell wall formation. Isoniazid should also be triggered via KatG, a bacterial catalase-peroxidase inhibitor within MTB<sup>[46]</sup>. Isoniazid would be bactericidal for separate mycobacteria quickly, yet is bacteriostatic when mycobacteria grow slowly. It inhibits the cytochrome P450 system and hence acts as a source of free radicals<sup>[47]</sup>. Rifampicin hinders bacterial DNA-based RNA growth through hindering bacterial DNA-dependent RNA polymerase. Rifampicin attachment throughout the RNA polymerase active site<sup>[48]</sup>. Mutation of amino acids shown in red are involved in resistance to the antibiotic. Mode of action: Ethambutol would be bacteriostatic for Tuberculosis bacilli which actively develop. This functions through hindering cell wall forming. Mycolic acids bind D-arabinose residues of arabinogalactan to the 5'-hydroxyl groups and form mycolyl-arabinogalactan-peptidoglycan compound within the cell wall. This prevents the formation of arabinogalactane while hindering the enzyme arabinosyl transferase. Disordering of the formation of arabinogalactans prevents the development from this compound as well as leads to greater permeability of the cell wall. Pyrazinamide is a prodrug that stops the growth of *M. tuberculosis*. Pyrazinamide diffuses into the granuloma of *M. TB*, in which the tuberculosis enzyme pyrazinamidase transforms pyrazinamide into the active state of pyrazinoic acid. Under acidic conditions of pH 5 to 6, the steadily leaking of pyrazinoic acid transforms into protonated conjugate acid, that is assumed to readily spread back into the bacilli also accumulate. The net effect is that high pyrazinoic acid builds up at acid pH within the bacillus than at a neutral pH.<sup>[49]</sup> The side effects of TB drugs depend on how drugs combine that are being taken. The side effects of anti-tuberculosis drugs may have mild and severe effects. A drug with a specifically severe side effect is streptomycin. This drug can cause people to become deaf and it should be avoided if at all possible. It should only be used for the treating of Drug Resistant TB when no other drug is available. It is excellent news that the category 2 TB treatment which was recommended by WHO for many years for people who had previously had treatment is now no longer recommended. Many patients previously given streptomycin and who went deaf as a result will no longer be given the drug. This is one of the reasons why it is essential that the new WHO recommendations are now always followed<sup>[50]</sup>

Conclusion: New biomarkers in TB are in desperate need at all of the various rates mentioned above. In conclusion, discovery studies of TB biomarkers are sometimes poorly planned, and results are scarcely verified in independent research. Few markers progress to an additional developmental stage. More confirmation studies are required to take into account the expected diagnostic use instances and apply rigorous design. This involves substantial participation from both academics and funders of the economy. There is no single test which can be used under any situations to test for TB. Most measurements are inexpensive but not very exact. Others can be used primarily when testing when TB and can't test for drug resistance. Some can be used to detect TB, such as the TB culture test, the new Genexpert TB test, and the TrueNat test, and they can also screen for certain types of drug resistance. Taken collectively, it is a systematic analysis which shows the TB host biomarker identifier that merits further validation in larger TB studies.

## REFERENCES:

- [1] Mitchell V. Palmer, Tyler C. Thacker, Meaghan M. Rabideau, Gareth J. Jones Carly Kanipe, H. Martin vardermeier, W. Ray waters, "Biomarkers of cell-mediated immunity to bovine tuberculosis" 2020

- [2] Micheal Phillips, Victoria Basa Dalay, Graham Bothamley, Renee N. Cataneo, Phung Kim Lom, Maria Piedad R. Natividad, Peter Schmitt, James Wai, "Breath biomarkers of active tuberculosis", 2010
- [3] Saurabh K. Shrivastva, Cess J.M. van Rijn and Marten A Jongsma, "Biosensor based detection of tuberculosis", 2016
- [4] TB incidence, prevalence, high burden, [tbfacts.org](http://tbfacts.org)  
Margarida Correia-Neves, Gabrielle Fröberg, Liudmyla Korshun, Sofia Viegas, Paula Vaz,
- [5] Nehaben Ramanlal, Judith Bruchfeld, Beston Hamasur, Patrick Brennan, and Gunilla Källenius, "Biomarkers for tuberculosis: the case for lipoarabinomannan", 2018
- [6] "TB test types", TB test, 2016
- [7] Yean K. Yong, Hong Y. Tan, Alireza Saeidi, Won F. Wong, Ramachandran Vignesh, Vijay Kumar Velu, Rajaraman Eri, Marie Larsson and Esaki M. Shankar, "Immune Biomarkers for Diagnosis and Treatment Monitoring of Tuberculosis: Current Developments and Future Prospects", 2019
- [8] Phillips M, Basa Dalay, Bothamley G, Cataneo RN, Lam PK, Natividad MP, Schmitt P, Wai J. "Breath biomarkers of active pulmonary tuberculosis", 2010.
- [9] Cattamanchi, Adithya Mohanty, Swomitra K, "Evaluation of a novel breath sensor for rapid, low-cost diagnosis of tuberculosis in children", 2018.
- [10] Phillips M, Basa-Dalay V, Bothamley G, "Breath biomarkers of active pulmonary tuberculosis. Tuberculosis" 2010
- [11] Luier L., Loots D.T. "Tuberculosis metabolomics reveals adaptations of man and microbe in order to outcompete and survive". *Metabolomics*. 2016
- [12] Flonza Isa, Sean Collins, Myung Hee Lee, Diessy Decome, Nancy Dorvil, Partrice Joseph, Lauren Smith, Stephen Salerno, Martin T. Wells, Steven Fischer, James M. Bean, Jean W. Pape, Warren D. Johnson, Daniel W. Fitzgerald, and Kyu Y. Rhee. "Mass Spectrometric Identification of Urinary Biomarkers of Pulmonary Tuberculosis", 2018
- [13] Wafaa S. El-Shimy, Adel S. Bediwy MD, Azza M. Hassan, Lamiaa R. Ismail, "Serum neopterin level in cases of pulmonary tuberculosis and pneumonia", 2016
- [14] Briken V, Porcelli SA, Besra GS, "Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response" 2004
- [15] Flores LL, Steingart KR, Dendukuri N, "Systematic review and meta-analysis of antigen detection tests for the diagnosis of tuberculosis". 2011
- [16] Conesa-Botella A, Loembe MM, Manabe YC, "Urinary lipoarabinomannan as predictor for the tuberculosis immune reconstitution inflammatory syndrome" 2011
- [17] Taylor TP, Janech MG, Slate EH, "Overcoming the effects of matrix interference in the measurement of urine protein analytes". 2012
- [18] Margarida Correia-Neves, Gabrielle Fröberg, Liudmyla Korshun, Sofia Viegas, Paula Vaz, Nehaben Ramanlal, Judith Bruchfeld, Beston Hamasur, Patrick Brennan, and Gunilla Källenius, "Biomarkers for tuberculosis: the case for lipoarabinomannan", 2018
- [19] Robert F. Luo, MD, MPH, Niaz Banaei, "Molecular approach and biomarkers for detection of Mycobacterium tuberculosis", 2013
- [20] Shreemanta K. Parida and Stefan H.E. Kaufmann, "The quest for biomarker in tuberculosis", 2010
- [21] Delia Goletti, Elisa Petruccioli, Siomine A. Joosten, Tom H.M. Ottenhoff, "Tuberculosis Biomarkers: From Diagnosis to Protection", 2016

- [22] Gernaey AM, Minnikin DE, Copley MS, Dixon RA, Middleton JC, Roberts CA, et al. Mycolic acids and ancient DNA confirm an osteological diagnosis of tuberculosis. *Tuberculosis*,2001
- [23] Magdalena druszczynska, Sebastian wawrocki, rafal szewczyk, wieslawa rudnicka, "Mycobacteria-derived biomarkers for tuberculosis diagnosis ",2016
- [24] Amanda Welin, Halla Björnsdottir, Malene Winther, Karin Christenson, Tudor Oprea, Anna Karlsson, Huamei Forsman, Claes Dahlgren, Johan Bylund "CFP-10 from Mycobacterium tuberculosis Selectively Activates Human Neutrophils through a Pertussis Toxin-Sensitive Chemotactic Receptor".
- [25] legesse m,ameni g,medhin g,mamo g,franken kl,ottenhoff th ,bjune g,abebe f. "IgA response to ESAT-6/CFP-10 and Rv2031 antigens varies in patients with culture-confirmed pulmonary tuberculosis, healthy Mycobacterium tuberculosis-infected and non-infected individuals in a tuberculosis endemic setting, Ethiopia",2013
- [26] Sambray,Devprasad Mohan,Ahmed,nayak,swaminathan,D'souza,jesuraj,dhar,babu, vyakarnam,Chandra,"unbiased identification of blood based biomarker for pulmonary tuberculosis by modeling and mining molecular interaction networks",2016
- [27] Cliff J.M.,Kaufmann S.H.,McShane H.,van Helden P.,O'Garra."the human immune response totuberculosis and its treatment:a view from the blood",2015
- [28] Moura EP,Toledo,Olivieria,Spindola-de-Miranda,Andrade ,Guimaraes,"Pulmonary tuberculosis: evaluation of interferon-gamma levels as an immunological healing marker based on the response to the Bacillus Calmette-Guerin",2004
- [29] Y.lopez-hernandez,O.patino-Rodriguez,S.T. Garcia-Orta,J.M. Pinos-rodriguez. "mass spectrometry applied to the identification of and biomarker discovery",2016
- [30] protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. *Microbes Infect*,2005
- [31] Chen DY, Shen GH, Chen YM, Chen HH, Lin CC, Hsieh CW, et al. "Interferoninducible protein-10 as a marker to detect latent and active tuberculosis in rheumatoid arthritis". 2011
- [32] Yassin MA, Petrucci R, Garie KT, Harper G, Arbide I, Aschalew M, " Can interferon-gamma or interferon-gamma-induced-protein-10 differentiate tuberculosis infection and disease in children of high endemic areas",2011
- [33] Ji Young Hong, Gyeong Seo Jung, Hyunjung Kim, Young Mi Kim, Hye Jon Lee, sang-Nae cho ,Se Kyu Kim , Joon Chang a, Young Ae Kang, "Efficacy of inducible protein 10 as a biomarker for the diagnosis of tuberculosis",2012.
- [34] Swierzko AS, Bartłomiejczyk MA, Brzostek A, Lukaszewicz J, Michalski M, Dziadek J, et al. "Mycobacterial antigen 85 complex (Ag85) as a target for ficolins and mannose-binding lectin". 2016
- [35] Magdalena Druszczynska, Sebastian Wawrocki,Rafal Szewczyk,and Wieslawa Rudnicka" Mycobacteria-derived biomarkers for tuberculosis diagnosis",2017
- [36] caiqin zhang ,xiaoqin song ,yong zhao,hai zhang,shanmin zhao, fengfeng mao , bing bai shaoping wu,changhong shi, "Mycobacterium tuberculosis Secreted Proteins As Potential Biomarkers for the Diagnosis of Active Tuberculosis and Latent Tuberculosis Infection",2014
- [37] N.Pitabut,S.Sakurada,T.Tanaka,C.Ridruechai,J.Tanuma,T.Aoki, "Poten-tialfunction Of granulysin,other related Effector molecules and lymphocyte subsets in patients with TB and HIV/TB coinfection", 2013



- [38] Giuliana Gugginoa,b,1,Valentina Orlando,a,b,1,Stella Cutrera,a,b, Marco P. La Mannaa,b, Diana Di Liberto,a,b,Valentina Vaninic, Elisa Petrucciolic, Francesco Dielia,b,Delia Golettic,Nadia Caccamo” Granzyme A as A potential Biomarker of Mycobacterium Tuberculosis infection and Disease “,2015
- [39] “TB Testing & Diagnosis”, CDC
- [40] “Guidelines for intensified case finding and isoniazid preventative therapy for people living with HIV in resource constrained settings”, Geneva, WHO, 2011
- [41] Davis, J Lucian “Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis 2012
- [42] Kirwan, Daniela E “Same-day diagnosis and treatment of tuberculosis”, 2012
- [43] Siddiqi, Kamran “Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence”, The Lancet Infectious Diseases, Vol 3, May 2003
- [44] “Tuberculosis (TB): Diagnosis”, National Jewish Health
- [45] “TB diagnosis: Improving the yield with fluorescence microscopy”, 2007  
46) Ahmad, Z., Klinkenberg, L.G., Pinn, M.L. "Biphasic Kill Curve of Isoniazid Reveals the Presence of Drug-Tolerant, Not Drug-Resistant, Mycobacterium tuberculosis in the Guinea Pig". 2009
- [46] Suarez, J. Ranguelova, K. Jarzecki, “an oxyferrous heme/protein-based radical intermediate is catalytically competent in the catalase reaction of mycobacterium tuberculosis catalase –peroxidase” 2009
- [47] Calvori C, Frontali L, Leoni L, Tecce G. "Effect of rifamycin on protein synthesis". Nature.
- [48] Whitfield, Michael G.; Soeters, Heidi M.; Warren, Robin M.; York, Talita; Sampson, Samantha L.; Streicher, Elizabeth M.; Helden, Paul D. van; Rie, Annelies van. "A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis"2015
- [49] tb-drugs,tbfacts.org